Schering-Plough Corporation (NYSE: SGP) today announced that the Peg-Intron® pre-filled pen (peginterferon alfa-2b) Single-dose Delivery System for the treatment of hepatitis C is being launched in Europe.
The introduction of the Peg-Intron pre-filled pen marks a major advancement in helping patients manage their disease. Each pre-filled pen Single-dose Delivery System will contain Peg-Intron at one of five different dosing strengths for a single use — 50 mcg, 80 mcg, 100 mcg, 120 mcg or 150 mcg. Maximum injection volume is 0.5 ml delivered through a very fine 30-gauge needle specifically designed to reduce patient discomfort often associated with needles utilized for subcutaneous injection.
“Schering-Plough is dedicated to providing innovative treatment options to patients with hepatitis C,” said Roch Doliveux, president of Schering-Plough International. “We are very pleased to offer patients in Europe the Peg-Intron pre-filled pen, which offers a convenient method for administering Peg-Intron. This may help patients adhere to their treatment regimens.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!